<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01762826</url>
  </required_header>
  <id_info>
    <org_study_id>INOS002</org_study_id>
    <nct_id>NCT01762826</nct_id>
  </id_info>
  <brief_title>Myo-inositol, D-chiro-inositol, and D-chiro/Myo-inositol in Gestational Diabetes</brief_title>
  <official_title>Adverse Obstetric Outcomes in Gestational Diabetes Mellitus and Inositol Stereoisomears</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G. d'Annunzio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Chieti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>G. d'Annunzio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of different inositol stereoisomears in preventing adverse obstetric outcomes in
      non-obese pregnant women at high risk for gestational diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators compared outcomes from metabolic and obstetric point of view in GDM
      pregnant non-obese patient with different stereoisomears of inositol supply. Dietary control
      and placebo or inositol steroisomears were administered starting at the enrolling time (first
      fasting oral glucose above 92 mg%; usually before 20 weeks gestations') till the delivery
      and/or pregnancy end/termination. Oral glucose tolerance test results at 24-28 weeks'
      gestation was evaluated (as glucose values and oGTT screening). Fetal growth, delivery data,
      obstetric outcomes and necessity of insulin therapy were taken into account.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OGTT result</measure>
    <time_frame>24-28 weeks' gestation</time_frame>
    <description>OGTT is the mainstay of obstetric outcomes in GDM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal measurements at third trimester</measure>
    <time_frame>28 weeks</time_frame>
    <description>Centiles of fetal measurements and amniotic fluid volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery data</measure>
    <time_frame>25-42 weeks gestations'</time_frame>
    <description>Gestational age at delivery Route of delivery Fetal gender Fetal weight (grams and centiles) Neonatal hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse obstetric outcome</measure>
    <time_frame>from first elevated oral fasting glucose (above 92 mg%) till the end/termination of pregnancy (latter 42 weeks gestation)</time_frame>
    <description>Abortion Preterm delivery Polyhydramnios IUGR Macrosomia Fetal distress Preterm delivery pPROM Neonatal morbility (NICU stay, low glucose levels, etc.) Neonatal mortality Cerebral palsy Route of delivery Dystocia Etc.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>GDM</condition>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <description>Diet pills of 400 mcg of acid folic daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-chiro-inositol / Myo-inositol</arm_group_label>
    <description>Diet sachets 2000 mg myo-inositol and 250 mg d-chiro-inositol and 400 mcg folic acid daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-chiro-inositol</arm_group_label>
    <description>Diet pills with 500 mg d-chiro-inositol and 400 mcg folic acid daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myo-inositol</arm_group_label>
    <description>Diet sachets with 2000 mg myo-inositol and 200 mcg folic acid twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol</intervention_name>
    <description>Dietary control plus Myo-inositol</description>
    <arm_group_label>Myo-inositol</arm_group_label>
    <other_name>Supplementation of myo-inositol plus dietary control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-chiro-inositol</intervention_name>
    <description>Dietary control plus D-Chiro-Inositol supplementation</description>
    <arm_group_label>D-chiro-inositol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-Chiro / Myo-inositol</intervention_name>
    <description>Dietary control Supplementation with myo and d-chiro inositol</description>
    <arm_group_label>D-chiro-inositol / Myo-inositol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dietary control plus folic acid 400 mcg daily</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Non obese pregnant women during first trimester of pregnancy with scared fasting glucose
        (above 92 mg%)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnancy below 20 weeks gestation BMI below 30 Fasting glucose between 92 and 126 mg%
             Singleton pregnancy Naturally conceived

        Exclusion Criteria:

          -  obese patient Fasti g glucose above 126 or below 92
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Celentano, MD</last_name>
    <role>Study Director</role>
    <affiliation>ObGyn Dept University of Chieti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Matarrelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ObGyn Dept Univ of Chieti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ester Vitacolonna, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Diabetology Dept Univ of Chieti</affiliation>
  </overall_official>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2013</study_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G. d'Annunzio University</investigator_affiliation>
    <investigator_full_name>Claudio Celentano</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Inositol</keyword>
  <keyword>GDM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

